1. Home
  2. EDSA vs MDRR Comparison

EDSA vs MDRR Comparison

Compare EDSA & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • MDRR
  • Stock Information
  • Founded
  • EDSA 2015
  • MDRR 2015
  • Country
  • EDSA Canada
  • MDRR United States
  • Employees
  • EDSA N/A
  • MDRR N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • MDRR Real Estate Investment Trusts
  • Sector
  • EDSA Health Care
  • MDRR Real Estate
  • Exchange
  • EDSA Nasdaq
  • MDRR Nasdaq
  • Market Cap
  • EDSA 6.0M
  • MDRR 13.9M
  • IPO Year
  • EDSA N/A
  • MDRR 2018
  • Fundamental
  • Price
  • EDSA $1.82
  • MDRR $12.95
  • Analyst Decision
  • EDSA Strong Buy
  • MDRR
  • Analyst Count
  • EDSA 1
  • MDRR 0
  • Target Price
  • EDSA $21.00
  • MDRR N/A
  • AVG Volume (30 Days)
  • EDSA 31.5K
  • MDRR 5.4K
  • Earning Date
  • EDSA 12-13-2024
  • MDRR 11-12-2024
  • Dividend Yield
  • EDSA N/A
  • MDRR 1.78%
  • EPS Growth
  • EDSA N/A
  • MDRR N/A
  • EPS
  • EDSA N/A
  • MDRR N/A
  • Revenue
  • EDSA N/A
  • MDRR $9,916,929.00
  • Revenue This Year
  • EDSA N/A
  • MDRR N/A
  • Revenue Next Year
  • EDSA N/A
  • MDRR N/A
  • P/E Ratio
  • EDSA N/A
  • MDRR N/A
  • Revenue Growth
  • EDSA N/A
  • MDRR N/A
  • 52 Week Low
  • EDSA $1.55
  • MDRR $8.24
  • 52 Week High
  • EDSA $5.99
  • MDRR $15.00
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 35.86
  • MDRR 55.74
  • Support Level
  • EDSA $1.55
  • MDRR $12.95
  • Resistance Level
  • EDSA $1.91
  • MDRR $13.99
  • Average True Range (ATR)
  • EDSA 0.14
  • MDRR 0.47
  • MACD
  • EDSA 0.04
  • MDRR 0.03
  • Stochastic Oscillator
  • EDSA 49.07
  • MDRR 40.60

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About MDRR Medalist Diversified REIT Inc.

Medalist Diversified REIT Inc is engaged in the acquisition, reposition, renovation, leasing, and managing of income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its principal objectives include sourcing value-added Investments in markets in which it maintains deep industry relationships and local market knowledge and the creation of value for stockholders by utilizing its relationships and local knowledge of commercial real estate investment, management, and disposition.

Share on Social Networks: